Irritable Bowel Syndrome with Diarrhea
📧 Sign up to get email alerts when something new happens for Irritable Bowel Syndrome with Diarrhea.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-04-13FDA Approved: VIBERZI — Supplemental Application (Allergan, Inc.)
FDA approves Allergan's supplemental application for VIBERZI (eluxadoline), expanding its regulatory approval.
-
CLINICAL_TRIALS withdrawal · 2017-06-20Clinical Trial Update: Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction [NA]
A trial of Saccharomyces cerevisiae CNCM I-3856 for irritable bowel syndrome with diarrhea and post-infectious bowel dysfunction has been wi…
-
FDA approval · 2017-04-20FDA Approved: VIBERZI — Supplemental Application (Allergan, Inc.)
FDA approved Allergan's supplemental application for VIBERZI (eluxadoline). This action approves changes requested in the supplement.
-
CLINICAL_TRIALS trial_result · 2017-04-18Clinical Trial Update: Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome [Phase 2, Phase 3]
Phase 2/3 trials of Tong-Xie-Yao-Fang Granules for diarrhea-predominant irritable bowel syndrome have completed.
-
CLINICAL_TRIALS trial_result · 2017-02-27Clinical Trial Update: Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]
A Phase 2 trial update reporting efficacy, safety and tolerability of DNK333 (25 mg twice daily) in women with diarrhea-predominant irritabl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-02-02FDA Approved: VIBERZI — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for VIBERZI (eluxadoline) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2017-01-18Clinical Trial Update: 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 3]
This Phase 3 52-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea was terminated, with result…
-
FDA approval · 2016-12-22FDA Approved: ALOSETRON HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a generic version of alosetron hydrochloride (alosetron) from Amneal Pharmaceuticals of New York LLC under an original ANDA.
-
CLINICAL_TRIALS trial_result · 2016-09-27Clinical Trial Update: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 3]
Phase 3 trial update showing 12-week efficacy and safety evaluation of ibodutant in women with irritable bowel syndrome with diarrhea; resul…
-
CLINICAL_TRIALS trial_result · 2016-09-05Clinical Trial Update: Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea [Phase 1, Phase 2]
Phase 1/Phase 2 trial results evaluating the Chang'an I Recipe for irritable bowel syndrome with diarrhea.
-
CLINICAL_TRIALS withdrawal · 2016-05-19Clinical Trial Update: 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 3]
A Phase 3 trial evaluating ibodutant for irritable bowel syndrome with diarrhea in women has been withdrawn.
-
FDA approval · 2015-12-15FDA Approved: LOPERAMIDE HYDROCHLORIDE — Original Application (Aurohealth LLC)
FDA approved the original application for loperamide hydrochloride from Aurohealth LLC, enabling generic access to the anti-diarrheal medica…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) [Phase 3]
A Phase 3 study evaluating YM060 for efficacy and safety in female patients with diarrhea-predominant irritable bowel syndrome has completed…
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study [Phase 3]
This entry reports a Phase 3 trial evaluating rifaximin re-treatment for irritable bowel syndrome with diarrhea and notes that results were …
-
FDA approval · 2014-03-12FDA Approved: XIFAXAN — Supplemental Application (Salix Pharmaceuticals, Inc.)
The FDA approved a supplemental application for XIFAXAN (rifaximin) filed by Salix Pharmaceuticals, Inc., resulting in an update to the prod…
-
CLINICAL_TRIALS trial_result · 2013-04-26Clinical Trial Update: Post-Infectious Irritable Bowel Syndrome (PI-IBS)
A completed clinical trial update on post-infectious irritable bowel syndrome (PI-IBS), focusing on the diarrhea-predominant form.
-
CLINICAL_TRIALS trial_result · 2013-03-25Clinical Trial Update: Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) [Phase 2]
Phase 2 study of ibodutant for irritable bowel syndrome with diarrhea has completed, and results were posted in 2013. The sponsor/manufactur…
-
CLINICAL_TRIALS trial_result · 2012-09-27Clinical Trial Update: Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea [Phase 2]
Phase 2 clinical trial update for mesalamine granules in irritable bowel syndrome with diarrhea has completed with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-01-24Clinical Trial Update: Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) [Phase 4]
Phase 4 trial investigating ondansetron for irritable bowel syndrome with diarrhea has been completed.
-
FDA approval · 2010-09-02FDA Approved: LOTRONEX — Supplemental Application (Legacy Pharma USA Inc.)
FDA approved a supplemental application for Lotronex (alosetron hydrochloride) submitted by Legacy Pharma USA Inc.
-
CLINICAL_TRIALS trial_result · 2009-06-11Clinical Trial Update: Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 3]
Phase 3 efficacy study of Rezular (Arverapamil) for irritable bowel syndrome with diarrhea has completed.
-
FDA approval · 2007-10-23FDA Approved: GOOD NEIGHBOR PHARMACY ANTI DIARRHEAL — Supplemental Application (Amerisource Bergen)
The FDA approved a supplemental application for Good Neighbor Pharmacy Anti Diarrheal containing loperamide HCl, submitted by AmerisourceBer…